Treatment of Rheumatoid Arthritis With Mammal Beta Defensins

ABSTRACT

The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.12/504,920, filed Jul. 17, 2009, allowed, which claims priority or thebenefit under 35 U.S.C. 119 of European application nos. EP08160761.6filed Jul. 18, 2008, and EP09160448.8 filed May 15, 2009, and U.S.provisional applications Nos. 61/086,910 filed Aug. 7, 2008, and61/179,517 filed May 19, 2009, the contents of which are fullyincorporated herein by reference.

REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form.The computer readable form is incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to prevention and treatment of rheumatoidarthritis by administration of a human beta defensin.

2. Background

Among many other elements, key components of innate immunity are theantimicrobial peptides (AMPs) that individually show considerableselectivity, but collectively are able to rapidly kill a broad spectrumof bacteria, viruses and fungi. The biological significance of AMPs isemphasized by their ubiquitous distribution in nature and they areprobably produced by all multicellular organisms. In humans thepredominant AMPs are the defensins. The human defensins are smallcationic peptides that can be divided into α- and β-defensins based onthe topology of their three intramolecular cysteine disulphide bonds.The α-defensins can be further subdivided into those that were firstisolated from neutrophil granules (HNP1-4) and those that are expressedby Paneth cells in the crypts of the small intestine (HD5 and HD6). Theβ-defensins are mainly produced by epithelial cells in various tissuesand organs including the skin, trachea, gastrointestinal tract,urogenital system, kidneys, pancreas and mammary gland. The bestcharacterized members of the β-defensin family are hBD1-3. However,using various bioinformatics tools almost 40 open reading framesencoding putative β-defensin homologues have been annotated in the humangenome. Some of the human defensins are produced constitutively, whereasothers are induced by proinflammatory cytokines or exogenous microbialproducts.

It has become increasingly clear that the human defensins in addition totheir direct antimicrobial activity also have a wide range ofimmunomodulatory/alternative properties. These include the induction ofvarious chemokines and cytokines, chemotactic and apoptotic activities,induction of prostaglandin, histamine and leukotriene release,inhibition of complement, stimulation of dendritic cell maturationthrough toll-like receptor signaling and stimulation of pathogenclearance by neutrophils. Furthermore, the human defensins also play arole in wound healing, proliferation of epithelial and fibroblast cells,angiogenesis and vasculogenesis.

There is increasing evidence that the human defensins play an importantrole in many infectious and inflammatory diseases. Overexpression ofhuman defensins is often observed in inflamed and/or infected skin mostlikely because of local induction by microbial components or endogenousproinflammatory cytokines. In psoriasis hBD2 and hBD3 are overabundantand in lesional epithelium of patients with acne vulgaris or superficialfolliculitis a significant upregulation of hBD2 has been observed. Onthe other hand, downregulation of hBD2 and hBD3 has been associated withatopic dermatitis.

Rheumatoid arthritis is a chronic, systemic inflammatory disorder thatmay affect many tissues and organs, but principally attacks the jointsproducing a inflammatory synovitis that often progresses to destructionof the articular cartilage and ankylosis of the joints. Rheumatoidarthritis can also produce diffuse inflammation in the lungs,pericardium, pleura, and sclera, and also nodular lesions, most commonin subcutaneous tissue under the skin. Although the cause of rheumatoidarthritis is unknown, autoimmunity plays a pivotal role in itschronicity and progression.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Defensin: The term “defensin” as used herein refers to polypeptidesrecognized by a person skilled in the art as belonging to the defensinclass of antimicrobial peptides. To determine if a polypeptide is adefensin according to the invention, the amino acid sequence may becompared with the hidden markov model profiles (HMM profiles) of thePFAM database by using the freely available HMMER software package.

The PFAM defensin families include for example Defensin_(—)1 or“Mammalian defensin” (accession no. PF00323), and Defensin_(—)2 orDefensin_beta or “Beta Defensin” (accession no. PF00711).

The defensins of the invention belong to the beta defensin class. Thedefensins from the beta defensin class share common structural features,such as the cysteine pattern.

Examples of defensins, according to the invention, include human betadefensin 1 (hBD1; see SEQ ID NO:1), human beta defensin 2 (hBD2; see SEQID NO:2), human beta defensin 3 (hBD3; see SEQ ID. NO:3), human betadefensin 4 (hBD4; see SEQ ID NO:4), and mouse beta defensin 3 (mBD3; seeSEQ ID NO:6).

Identity: The relatedness between two amino acid sequences or betweentwo nucleotide sequences is described by the parameter “identity”.

For purposes of the present invention, the degree of identity betweentwo amino acid sequences is determined using the Needleman-Wunschalgorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,Trends in Genetics 16: 276-277; http://emboss.org), preferably version3.0.0 or later. The optional parameters used are gap open penalty of 10,gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version ofBLOSUM62) substitution matrix. The output of Needle labeled “longestidentity” (obtained using the-nobrief option) is used as the percentidentity and is calculated as follows:

(Identical Residues×100)/(Length of Alignment−Total Number of Gaps inAlignment)

For purposes of the present invention, the degree of identity betweentwo deoxyribonucleotide sequences is determined using theNeedleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) asimplemented in the Needle program of the EMBOSS package (EMBOSS: TheEuropean Molecular Biology Open Software Suite, Rice et al., 2000,supra; http://emboss.org), preferably version 3.0.0 or later. Theoptional parameters used are gap open penalty of 10, gap extensionpenalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4)substitution matrix. The output of Needle labeled “longest identity”(obtained using the-nobrief option) is used as the percent identity andis calculated as follows:

(Identical Deoxyribonucleotides×100)/(Length of Alignment−Total Numberof Gaps in Alignment).

Isolated polypeptide: The term “isolated variant” or “isolatedpolypeptide” as used herein refers to a variant or a polypeptide that isisolated from a source. In one aspect, the variant or polypeptide is atleast 1% pure, preferably at least 5% pure, more preferably at least 10%pure, more preferably at least 20% pure, more preferably at least 40%pure, more preferably at least 60% pure, even more preferably at least80% pure, and most preferably at least 90% pure, as determined bySDS-PAGE.

Substantially pure polypeptide: The term “substantially purepolypeptide” denotes herein a polypeptide preparation that contains atmost 10%, preferably at most 8%, more preferably at most 6%, morepreferably at most 5%, more preferably at most 4%, more preferably atmost 3%, even more preferably at most 2%, most preferably at most 1%,and even most preferably at most 0.5% by weight of other polypeptidematerial with which it is natively or recombinantly associated. It is,therefore, preferred that the substantially pure polypeptide is at least92% pure, preferably at least 94% pure, more preferably at least 95%pure, more preferably at least 96% pure, more preferably at least 96%pure, more preferably at least 97% pure, more preferably at least 98%pure, even more preferably at least 99%, most preferably at least 99.5%pure, and even most preferably 100% pure by weight of the totalpolypeptide material present in the preparation. The polypeptides of thepresent invention are preferably in a substantially pure form. This canbe accomplished, for example, by preparing the polypeptide by well-knownrecombinant methods or by classical purification methods.

Mammal Beta Defensins

The present invention relates to pharmaceutical uses of mammal betadefensins, such as human beta defensins and/or mouse beta defensins, inthe treatment of rheumatoid arthritis. The treatment is preferablyassociated with reduced TNF-alpha activity in treated tissues.

In an embodiment, the mammal beta defensins of the invention have adegree of identity of at least 80%, preferably at least 85%, morepreferably at least 90%, and most preferably at least 95% to any of theamino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ IDNO:4, SEQ ID NO:5 and/or SEQ ID NO:6. In a preferred embodiment, themammal beta defensins of the invention have a degree of identity of atleast 80%, preferably at least 85%, more preferably at least 90%, andmost preferably at least 95% to any of the amino acid sequences of SEQID NO:1, SEQ ID NO:2, SEQ ID NO:3 and/or SEQ ID NO:4. In a morepreferred embodiment, the mammal beta defensins of the invention consistof human beta defensin 1 (SEQ ID NO:1), human beta defensin 2 (SEQ IDNO:2), human beta defensin 3 (SEQ ID NO:3), human beta defensin 4 (SEQID NO:4), a variant of human beta defensin 4 (SEQ ID NO:5) and/or mousebeta defensin 3 (SEQ ID NO:6). In an even more preferred embodiment, themammal beta defensins of the invention consist of human beta defensin 1(SEQ ID NO:1), human beta defensin 2 (SEQ ID NO:2), human beta defensin3 (SEQ ID NO:3) and/or human beta defensin 4 (SEQ ID NO:4).

In another embodiment, the mammal beta defensins of the invention have adegree of identity of at least 80%, preferably at least 85%, morepreferably at least 90%, and most preferably at least 95% to the aminoacid sequence of SEQ ID NO:2. In a preferred embodiment, the mammal betadefensins of the invention consist of human beta defensin 2 (SEQ IDNO:2).

In yet another embodiment, the mammal beta defensins of the inventionconsist of human beta defensins and/or mouse beta defensins, andfunctionally equivalent variants thereof. Preferably, the mammal betadefensins consist of human beta defensin 1, human beta defensin 2, humanbeta defensin 3, human beta defensin 4 and mouse beta defensin 3, andfunctionally equivalent variants thereof. More preferably, the mammalbeta defensins of the invention consist of human beta defensin 2, andfunctionally equivalent variants thereof.

The mammal beta defensins of the invention are also referred to ascompounds of the preferred embodiments.

In the context of the present invention, a “functionally equivalentvariant” of a mammal (e.g. human) beta defensin is a modified mammal(e.g. human) beta defensin exhibiting approx. the same effect onrheumatoid arthritis as the parent mammal (e.g. human) beta defensin.Preferably, it also exhibits approx. the same effect on TNF-alphaactivity as the mammal (e.g. human) beta defensin.

According to the invention, a functionally equivalent variant of amammal (e.g. human) beta defensin may comprise 1-5 amino acidmodifications, preferably 1-4 amino acid modifications, more preferably1-3 amino acid modifications, most preferably 1-2 amino acidmodification(s), and in particular one amino acid modification, ascompared to the mammal (e.g. human) beta defensin amino acid sequence.

The term “modification” means herein any chemical modification of amammal (e.g. human) beta defensin. The modification(s) can besubstitution(s), deletion(s) and/or insertions(s) of the amino acid(s)as well as replacement(s) of amino acid side chain(s); or use ofunnatural amino acids with similar characteristics in the amino acidsequence. In particular the modification(s) can be amidations, such asamidation of the C-terminus.

Preferably, amino acid modifications are of a minor nature, that isconservative amino acid substitutions or insertions that do notsignificantly affect the folding and/or activity of the polypeptide;single deletions; small amino- or carboxyl-terminal extensions; a smalllinker peptide of up to about 20-25 residues; or a small extension thatfacilitates purification by changing net charge or another function,such as a poly-histidine tag, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basicamino acids (arginine, lysine and histidine), acidic amino acids(glutamic acid and aspartic acid), polar amino acids (glutamine andasparagine), hydrophobic amino acids (leucine, isoleucine and valine),aromatic amino acids (phenylalanine, tryptophan and tyrosine), and smallamino acids (glycine, alanine, serine, threonine and methionine). Aminoacid substitutions which do not generally alter specific activity areknown in the art and are described, for example, by H. Neurath and R. L.Hill, 1979, In, The Proteins, Academic Press, New York. The mostcommonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser,Ala/Gly, Ala/Thr, Ser/Asn, AlaNal, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg,Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

In addition to the 20 standard amino acids, non-standard amino acids(such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid,isovaline, and alpha-methyl serine) may be substituted for amino acidresidues of a wild-type polypeptide. A limited number ofnon-conservative amino acids, amino acids that are not encoded by thegenetic code, and unnatural amino acids may be substituted for aminoacid residues. “Unnatural amino acids” have been modified after proteinsynthesis, and/or have a chemical structure in their side chain(s)different from that of the standard amino acids. Unnatural amino acidscan be chemically synthesized, and preferably, are commerciallyavailable, and include pipecolic acid, thiazolidine carboxylic acid,dehydroproline, 3- and 4-methylproline, and 3,3-dimethylproline.

Essential amino acids in the mammal beta defensins can be identifiedaccording to procedures known in the art, such as site-directedmutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989,Science 244: 1081-1085). In the latter technique, single alaninemutations are introduced at every residue in the molecule, and theresultant mutant molecules are tested for biological activity (i.e.,activity against rheumatoid arthritis) to identify amino acid residuesthat are critical to the activity of the molecule. See also, Hilton etal., 1996, J. Biol. Chem. 271: 4699-4708. The identities of essentialamino acids can also be inferred from analysis of identities withpolypeptides which are related to mammal (e.g. human) beta defensins.

Single or multiple amino acid substitutions can be made and tested usingknown methods of mutagenesis, recombination, and/or shuffling, followedby a relevant screening procedure, such as those disclosed byReidhaar-Olson and Sauer, 1988, Science 241: 53-57; Bowie and Sauer,1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413; or WO95/22625. Other methods that can be used include error-prone PCR, phagedisplay (e.g., Lowman et al., 1991, Biochem. 30:10832-10837; U.S. Pat.No. 5,223,409; WO 92/06204), and region-directed mutagenesis (Derbyshireet al., 1986, Gene 46:145; Ner et al., 1988, DNA 7:127).

An N-terminal extension of the polypeptides of the invention maysuitably consist of from 1 to 50 amino acids, preferably 2-20 aminoacids, especially 3-15 amino acids. In one embodiment N-terminal peptideextension does not contain an Arg (R). In another embodiment theN-terminal extension comprises a kex2 or kex2-like cleavage site as willbe defined further below. In a preferred embodiment the N-terminalextension is a peptide, comprising at least two Glu (E) and/or Asp (D)amino acid residues, such as an N-terminal extension comprising one ofthe following sequences: EAE, EE, DE and DD.

Methods and Uses

Human beta defensin 2 was found to significantly reduce the severity ofdisease parameters in a 41-Day collagen-induced rheumatoid arthritismodel in the mouse; thus showing potent activity as a medicament fortreatment of rheumatoid arthritis.

The present invention therefore provides methods of treating rheumatoidarthritis, which treatment comprises administering to a subject in needof such treatment an effective amount of a mammal beta defensin,preferably a human beta defensin, more preferably human beta defensin 2,e.g., in the form of a pharmaceutical composition. Also provided aremammal beta defensins, preferably human beta defensins, more preferablyhuman beta defensin 2, for the manufacture of a medicament, and the useof mammal beta defensins, preferably human beta defensins, morepreferably human beta defensin 2, for the manufacture of a medicamentfor the treatment of rheumatoid arthritis. Treatment includes treatmentof an existing disease or disorder, as well as prophylaxis (prevention)of a disease or disorder.

Mammal beta defensins can be employed therapeutically in compositionsformulated for administration by any conventional route, includingenterally (e.g., buccal, oral, nasal, rectal), parenterally (e.g.,intravenous, intracranial, intraperitoneal, subcutaneous, orintramuscular), or topically (e.g., epicutaneous, intranasal, orintratracheal). Within other embodiments, the compositions describedherein may be administered as part of a sustained release implant.

Within yet other embodiments, compositions, of preferred embodiments maybe formulized as a lyophilizate, utilizing appropriate excipients thatprovide stability as a lyophilizate, and subsequent to rehydration.

Pharmaceutical compositions containing a mammal beta defensin can bemanufactured according to conventional methods, e.g., by mixing,granulating, coating, dissolving or lyophilizing processes.

Pharmaceutical compositions of preferred embodiments comprise a mammalbeta defensin and a pharmaceutically acceptable carrier and/or diluent.

A mammal beta defensin is preferably employed in pharmaceuticalcompositions in an amount which is effective to treat rheumatoidarthritis, preferably with acceptable toxicity to the patient. For suchtreatment, the appropriate dosage will, of course, vary depending upon,for example, the chemical nature and the pharmacokinetic data of acompound of the present invention used, the individual host, the mode ofadministration and the nature and severity of the conditions beingtreated. However, in general, for satisfactory results in largermammals, for example humans, an indicated daily dosage is preferablyfrom about 0.001 mg/kg body weight to about 100 mg/kg body weight,preferably from about 0.01 mg/kg body weight to about 50 mg/kg bodyweight, more preferably from about 0.05 mg/kg body weight to about 20mg/kg body weight, and most preferably from about 0.1 mg/kg body weightto about 10 mg/kg body weight, for example, administered in divideddoses up to one, two, three, or four times a day. The compounds ofpreferred embodiments can be administered to larger mammals, for examplehumans, by similar modes of administration at similar dosages thanconventionally used.

In certain embodiments, the pharmaceutical compositions of preferredembodiments can include mammal beta defensins, such as human betadefensins, in an amount of about 0.5 mg or less to about 1500 mg or moreper unit dosage form depending upon the route of administration,preferably from about 0.5, 0.6, 0.7, 0.8, or 0.9 mg to about 150, 200,250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1000 mg, and morepreferably from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg toabout 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg.In certain embodiments, however, lower or higher dosages than thosementioned above may be preferred. Appropriate concentrations and dosagescan be readily determined by one skilled in the art.

Pharmaceutically acceptable carriers and/or diluents are familiar tothose skilled in the art. For compositions formulated as liquidsolutions, acceptable carriers and/or diluents include saline andsterile water, and may optionally include antioxidants, buffers,bacteriostats, and other common additives. The compositions can also beformulated as pills, capsules, granules, tablets (coated or uncoated),(injectable) solutions, solid solutions, suspensions, dispersions, soliddispersions (e.g., in the form of ampoules, vials, creams, gels, pastes,inhaler powder, foams, tinctures, lipsticks, drops, sprays, orsuppositories). The formulation can contain (in addition to a mammalbeta defensin, and other optional active ingredients) carriers, fillers,disintegrators, flow conditioners, sugars and sweeteners, fragrances,preservatives, stabilizers, wetting agents, emulsifiers, solubilizers,salts for regulating osmotic pressure, buffers, diluents, dispersing andsurface-active agents, binders, lubricants, and/or other pharmaceuticalexcipients as are known in the art. One skilled in this art may furtherformulate a mammal beta defensin in an appropriate manner, and inaccordance with accepted practices, such as those described inRemington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co.,Easton, Pa. 1990.

A mammal beta defensin can be used alone, or in combination therapieswith one, two, or more other pharmaceutical compounds or drugsubstances, and/or with one or more pharmaceutically acceptableexcipient(s).

In Vitro Synthesis

Mammal beta defensins may be prepared by in vitro synthesis, usingconventional methods as known in the art. Various commercial syntheticapparatuses are available, for example automated synthesizers by AppliedBiosystems Inc., Beckman, etc. By using synthesizers, naturallyoccurring amino acids may be substituted with unnatural amino acids,particularly D-isomers (or D-forms) e.g. D-alanine and D-isoleucine,diastereoisomers, side chains having different lengths orfunctionalities, and the like. The particular sequence and the manner ofpreparation will be determined by convenience, economics, purityrequired, and the like.

Chemical linking may be provided to various peptides or proteinscomprising convenient functionalities for bonding, such as amino groupsfor amide or substituted amine formation, e.g. reductive amination,thiol groups for thioether or disulfide formation, carboxyl groups foramide formation, and the like.

If desired, various groups may be introduced into the peptide duringsynthesis or during expression, which allow for linking to othermolecules or to a surface. Thus cysteines can be used to makethioethers, histidines for linking to a metal ion complex, carboxylgroups for forming amides or esters, amino groups for forming amides,and the like.

Mammal beta defensins may also be isolated and purified in accordancewith conventional methods of recombinant synthesis. A lysate may beprepared of the expression host and the lysate purified using HPLC,exclusion chromatography, gel electrophoresis, affinity chromatography,or other purification technique.

The present invention is further described by the following examplesthat should not be construed as limiting the scope of the invention.

EXAMPLES Example 1 Evaluation of Human Beta Defensin 2 in aCollagen-Induced Rheumatoid Arthritis Model

During testing of hBD2 for immunomodulatory effects it was unexpectedlyobserved that hBD2 had vast anti-inflammatory potential.

Here, we have shown that hBD2 has significant effect in treatingrheumatoid arthritis in a collagen-induced rheumatoid arthritis model inthe mouse.

Human Beta Defensin 2 (hBD2)

hBD2 was produced recombinantly. A synthetic DNA fragment (DNA 2.0)encoding hBD2 was cloned into the pET-32(+) expression vector (Novagen).The resulting plasmid encoded a translational fusion peptide containingan N-terminal thioredoxin part followed by a his-tag, an enterokinasecleavage site and finally the hBD2 peptide. The expression plasmid wastransformed into E. coli strain BL21.

An overnight culture of this strain was diluted 100 fold in TB-glycerolcontaining 100 μg/ml of ampicillin and grown to an OD600 ofapproximately 8 at 37° C. and induced with 0.5 mM of IPTG for 3 hoursafter which the cells were harvested by centrifugation. The his-taggedtrx-hBD2 fusion peptide was purified on Ni-NTA beads (QIAGEN) usingstandard protocols. The his-tag purified fusion peptide was subsequentlydialysed over-night into enterokinase buffer (50 mM tris-HCl pH 7.5, 1mM CaCl₂) and cleaved with enterokinase to release mature hBD2. The hBD2peptide was further purified by cation-exchange chromatography usingSource 15 S matrix (Amersham Biosciences). The correct molecular weightof hBD2 was verified using MALDI-TOF mass spectrometry.

Production of mBD3 (see Example 5) was carried out using an identicalprotocol.

The proper folding and disulphide-bridge topology of the hBD2 moleculewas subsequently verified using tryptic digestion coupled with LC-MS andNMR spectroscopy.

Endotoxin was removed by preparative RP-HPLC at low pH, and the contentof endotoxin was determined by a LAL assay (Endosafe KTA2) and the levelwas found to be below the detection limit of the assay (0.05 EU/mg). Toascertain that levels below the detection limit of the endotoxin assaywere not able to stimulate PBMC, titration curves of stimulation with avery potent lipopolysaccharide (E. coli, O111:B4, Sigma L4391) wereperformed. Very low levels of this LPS (0.06 pg/ml) were able tostimulate PBMC to a detectable cytokine production.

The aim of the following study was to determine the anti-inflammatoryactivity of human beta defensin 2 in rheumatoid arthritis.

Test System

-   Species/Strain: Mouse/DBA/1-   Source: Harlan, UK-   Gender: Male-   No. of Animals: n=50-   Age: Young adults, 6-8 weeks of age at study initiation.-   Body Weight: Weight variation of study animals at the time of    collagen induction did not exceed ±20% of the mean weight.-   Animals Health The health status of the animals used in this study    was examined on arrival. Only animals in good health were    acclimatized to laboratory conditions and were used in the study.-   Acclimatization: At least 7 days.-   Housing: During acclimatization and following dosing, animals were    housed within a limited access rodent facility and kept in groups of    maximum 10 mice, in polypropylene cages (45 cm×25 cm×13 cm), fitted    with solid bottoms and filled with wood shavings as bedding    material. Cages were changed once weekly.-   Food and Water: Animals were provided ad libitum a commercial rodent    diet and free access to drinking water, supplied to each cage via    polyethylene bottles with stainless steel sipper tubes. Water    bottles were changed at least every 3 weeks. Water was changed 3    times per week.-   Environment: Automatically controlled environmental conditions were    set to maintain temperature at 20-24° C. with a relative humidity    (RH) of 30-70%, a 12/12 hour light/dark cycle and 10-30 air    changes/hr in the study room. Temperature and RH was monitored daily    by both manual measurements and the control computer. The light    cycle was monitored by the control computer.-   Identification: Animals were given a unique animal identification    ear number. This number also appeared on a cage card, visible on the    front of each cage. The cage card also contained the study number.-   Randomization: Animals were randomly assigned to experimental    groups.-   Termination: At the end of the study surviving animals were    euthanized by O₂/CO₂ inhalation, followed by exsanguination.-   Justification: The mouse was selected since it represented the    species of choice for this experimental animal model. The DBA/1    strain of mouse is highly susceptible to collagen-induced arthritis    (CIA).

Materials

Human Beta Defensin 2 (hBD2); see aboveDexamethasone (Sigma, cat. no. D1756)

Bovine Type II Collagen (MD Biosciences, cat. no. 804001314) CompleteFreund's Adjuvant (CFA) (MD Biosciences, cat. no. 501009703)

PBS (PAA, cat no. H15-002)

Constitution of Test Groups

TABLE 1 Test groups and treatments. Group Group Test size no. compoundRoute Dose Volume Regime n = 10 A Vehicle IV 0 mg/kg 5 mL/kg oncecontrol daily n = 10 B Dexa- IP 1 mg/kg 5 mL/kg once methasone daily n =10 C hBD2 IV 10 mg/kg  5 mL/kg once daily n = 10 D hBD2 IV 1 mg/kg 5mL/kg once daily n = 10 E hBD2 IV 0.1 mg/kg   5 mL/kg once daily IV:intravenous IP: intraperitoneal

Test Procedures Arthritis Induction

All animals were subjected on Day 0 of the study (study commencement) toan intradermal injection into the tail of 0.1 ml Type II Collagen/CFAemulsion (200 μg collagen per mouse) under light Isoflurane anesthesia,using a plastic syringe. The location of injection was at an approximatecaudal distance of about 1 cm from the base of the tail. A collagenchallenge (200 μg/mouse) was presented to the animals by IP injection ofcollagen and PBS on Day 21.

Treatment

Treatments were commenced on day 14 of the study and continued oncedaily throughout. All surviving mice were terminated on study day 42.

Route of Administration:

(i) hBD2: Intravenous

(ii) Dexamethasone: Intraperitoneal

(iii) Vehicle Control: Intravenous

Dose and Volume Dosage (See Also Table 1):

(i) hBD2: 10, 1 or 0.1 mg/kg at 5 mL/kg(ii) Dexamethasone: 1 mg/kg at 5 mL/kg(iii) Vehicle Control: 0 mg/kg at 5 mL/kgAnalgesia: No analgesic was used during the study.

Observations and Examinations Arthritis Reactions

Mice were examined for signs of arthritogenic responses in peripheraljoints on study day 0, 14, 21 and thereafter five times weekly untiltermination of the study. Arthritis reactions were reported for each pawaccording to a 0-4 scale in ascending order of severity as shown below:

Arthritis Score Grade No reaction, normal: 0 Mild, but definite rednessand swelling of the ankle/wrist or 1 apparent redness and swellinglimited to individual digits, regardless of the number of affecteddigits: Moderate to severe redness and swelling of the ankle/wrist: 2Redness and swelling of the entire paw including digits: 3 Maximallyinflamed limb with involvement of multiple joints: 4

Clinical Signs

On Day 0, 14, 21 and thereafter five times weekly, careful clinicalexaminations were carried out and recorded. Observations includedchanges in skin, fur, eyes, mucous membranes, occurrence of secretionsand excretions (e.g. diarrhea) and autonomic activity (e.g. lacrimation,salivation, piloerection, pupil size, unusual respiratory pattern).Changes in gait, posture and response to handling, as well as thepresence of bizarre behavior, tremors, convulsions, sleep and coma werealso noted.

Prior to day 14 mice were monitored daily for any unusual behaviour.

Body Weights

Determination of individual body weights of animals were made shortlybefore Arthritis induction on Day 0, 14, 21 and thereafter five timesweekly until the termination of the study.

Measurement of Experimental Arthritis

The relative change in both hind paw thickness (left and right, justbelow the foot pad and above the calcaneum) of each animal was measuredin mm on study days 0, 14, 21 and thereafter five times per week using adial caliper (Kroeplin, Munich, Germany).

Study Termination

All mice were terminated on study day 42.

Sample Collection

At study termination, following O₂/CO₂ inhalation, terminal bloodsamples were obtained from all remaining study animals. Serum wasprepared from each sample and stored at −20° C. In addition, the leftfront and rear paws were collected and stored in formalin, and the rightfront and rear paws were collected and snap frozen for possible jointRNA analysis.

Humane Endpoints

Animals found in a moribund condition and animals showing severe painand enduring signs of severe distress were humanely euthanized. Inaddition, animals showing a decrease of body weight larger than 20% frominitial body weight determination were humanely euthanized. Mice with atotal arthritic score of 12 or higher were also culled for humanereasons. All animals were euthanized by O₂/CO₂ inhalation, followed byexsanguination. Paw samples and terminal blood samples were obtainedfrom all study animals.

Statistical Analysis

Evaluation was primarily based on the mean values for arthritis scoresand paw thickness measurements. Where appropriate, analysis of the databy appropriate statistical methods was applied to determine significanceof treatment effects. ANOVA followed by Tukey post-hoc analysis (Winstat2005.1 for Excel) was used to assess statistical differences betweentreatment groups.

In accordance with Home Office regulations mice with a total clinicalscore of equal to or greater than 12 were culled due to arthritisseverity. The clinical score of these mice at termination was carriedforward in the analysis for the remainder of the study in order that thedata was not artificially skewed by the removal of high scoring mice.

Animal Care and Use Statement

This study was performed according to the UK Home Office regulations foruse of animals in scientific procedures.

Results

TABLE 2 Mean clinical arthritis scores determined during the 42 dayobservation period in the collagen induced male DBA/1 arthritic mice.Group B Group C Group D Group E Study Group A Dexamethasone hBD2 hBD2hBD2 Day Data Vehicle 1 mg/kg 10 mg/kg 1 mg/kg 0.1 mg/kg 0 MeanArthritic 0.0 0.0 0.0 0.0 0.0 Score SEM 0.0 0.0 0.0 0.0 0.0 14 MeanArthritic 0.1 0.4 1.7 0.6 1.2 Score SEM 0.1 0.2 0.6 0.3 0.5 21 MeanArthritic 3.2 0.0 3.1 2.1 3.2 Score SEM 1.2 0.0 1.1 0.8 1.3 22 MeanArthritic 3.4 0.0 4.3 2.3 3.6 Score SEM 1.1 0.0 1.1 0.8 1.4 23 MeanArthritic 3.4 0.0 3.3 2.0 3.2 Score SEM 1.1 0.0 1.2 0.7 1.3 26 MeanArthritic 4.4 0.0* 4.1 2.0 3.7 Score SEM 1.1 0.0 1.2 0.7 1.3 27 MeanArthritic 4.8 0.0* 4.1 2.0 4.1 Score SEM 1.2 0.0 1.3 0.7 1.3 28 MeanArthritic 5.3 0.0* 4.1 2.3 4.4 Score SEM 1.1 0.0 1.2 0.8 1.3 29 MeanArthritic 6.3 0.0* 4.4 2.4 5.0 Score SEM 1.1 0.0 1.3 0.8 1.3 30 MeanArthritic 6.8 0.0* 4.9 2.7 5.9 Score SEM 1.1 0.0 1.3 0.9 1.5 33 MeanArthritic 7.4 0.0* 4.8 4.0 7.3 Score SEM 1.1 0.0 1.2 0.9 1.4 34 MeanArthritic 7.3 0.0* 4.9 4.1 7.8 Score SEM 1.1 0.0 1.2 1.1 1.3 35 MeanArthritic 7.5 0.0* 4.9 4.0 8.0 Score SEM 1.0 0.0 1.2 1.1 1.3 36 MeanArthritic 6.8 0.0* 4.8 4.1 8.2 Score SEM 0.9 0.0 1.1 1.1 1.1 37 MeanArthritic 7.4 0.0* 4.7 4.2 8.7 Score SEM 0.9 0.0 1.1 1.1 1.1 40 MeanArthritic 8.2 0.0* 5.0 4.7* 9.0 Score SEM 0.8 0.0 1.0 1.2 0.8 41 MeanArthritic 8.5 0.0* 4.8* 5.2 8.8 Score SEM 0.7 0.0 1.0 1.1 0.8 *p < 0.05significantly different from Vehicle group

CONCLUSION

Arthritic reactions were noted in all groups from study day 14. Meantotal arthritis scores (Table 2) for vehicle treated mice peaked at8.5±0.72 on study day 41. Mean total arthritis scores in mice treatedwith hBD2 at 10 mg/kg (Group C) peaked at 5.0±1.04 on study day 40. Meanarthritis scores in this group were lower compared to vehicle treatedmice from day 23 until the end of study, however only significantly onstudy day 41.

Mean total arthritis scores in mice treated with hBD2 at 1 mg/kg (GroupD) peaked at 5.2±1.11 on study day 41 and were consistently lowercompared to the vehicle treated group from day 21 until the end ofstudy, however only significantly on day 40. Treatment of mice with hBD2at 0.1 mg/kg (Group E) did not significantly lower mean total arthritisscores compared to the vehicle treated group. The mean score in thisgroup peaked at 9.0±0.77 on study day 40. Mice in the dexamethasonetreated group (Group B) displayed a significantly lower arthritic scorecompared to the vehicle treated group from study day 26 until the end ofthe study.

To ensure that the removal of mice culled early in the study due toarthritis severity did not artificially skew the data, arthritis scoresfrom such mice were carried over in the analysis until studytermination.

Example 2

Anti-Inflammatory Activity of Human Beta Defensin 2 (hBD2)

In human PBMC cultures it was observed that treatment with hBD2 hadgreat influence on the cytokine profile of LPS, LTA or peptidoglycanstimulated cultures. It has previously been observed that hBD2 is ableto induce the proinflammatory cytokines and chemokines IL-6, IL-1β,RANTES, IP-10 and IL-8 (Niyonsaba et al. 2007, Boniotto M. et al. 2006).

Here we show that hBD2 has downregulating potential on TNF and IL-1β,two proinflammatory cytokines; and hBD2 also induces IL-10 uponinduction of an inflammatory stimulus with lipopolysaccahride (LPS),lipoteichoic acid (LTA) or peptidoglycan (PGN). IL-10 is a potentialanti-inflammatory cytokine and hence the resulting effect of hBD2 isanti-inflammatory. This has been observed for human PBMC, a monocyticcell line and a dendritoid cell line.

hBD2 was prepared as described in Example 1.

Isolation and Stimulation of PBMC.

Peripheral blood was drawn from healthy volunteers (with approval fromthe relevant ethical committee in Denmark). Heparinized blood wasdiluted 1/1 v/v with RPMI and were subjected to Ficoll densitycentrifugation within 2 h of drawing. Plasma was collected from the topfrom individual donors and was kept on ice until it was used at 2% inthe culture medium (autologous culture medium). Isolated PBMC wereresuspended in autologous culture medium and seeded in 96-well cultureplates with 255.000 cells per well in a total of 200 μl. PBMC from thesame donor were stimulated with 100, 10 or 1 μg/ml of hBD2 either aloneor together with LPS at 0.6 ng/ml or 20 ng/ml (E. coli, O111:B4, SigmaL4391), Lipoteichoic acid (LTA) at 1.25 μg/ml (from B. subtilis, SigmaL3265) or peptidoglycan (PGN) at 40 μg/ml (from S. aureus, Sigma 77140).The concentrations used for stimulation were optimized on 3 differentdonors in initial experiments, for LPS two different concentrations wereused to be sure to be on a cytokine level that is possible to modulate.In some experiments PBMC were treated with Dexamethason and Indomethacinalone and together with LPS or LTA as a control on downregulation ofinflammatory cytokines. The supernatants were collected after incubationat 37° C. for 24 hours, and stored at −80° C. until cytokinemeasurement. Viability was measured by Alamar Blue (Biosource, DALL1100) in all experiments and in some cases also by MTS (Promega)according to manufacturer's instruction and was in some experiments alsojudged by counting of the cells by a Nucleocounter.

Culture and Stimulation of MUTZ-3

The human myeloid leukaemia-derived cell line MUTZ-3 (DSMZ,Braunschweig, Germany) was maintained in a-MEM (Sigma M4526),supplemented with 20% [volume/volume (v/v)] fetal bovine serum (SigmaF6178) and 40 ng/ml rhGM-CSF (R&D Systems 215-GM-050). These progenitorcells is in the following denoted monocyte cell line and these monocyteswere stimulated with 100, 10 or 1 μg/ml of hBD2 either alone or togetherwith LPS or LTA.

Dendritic Cell Differentiation

To generate a dendritoid cell line, the human myeloid leukaemia celllines MUTZ-3 (1×10⁵ cells/ml) was differentiated for 7 days in thepresence of rhGM-CSF (150 ng/ml) and rhIL-4 (50 ng/ml) into immatureDCs. Medium was exchanged every 2-3 days. The differentiated cell linewas further stimulated with either LPS or LTA with and without hBD2 toexplore the effect of hBD2 on dendritic cells.

Cytokine Measurements.

Cytokine production in supernatants was measured by flow cytometry witha human inflammation cytometric bead array (CBA) according tomanufacturer's instructions (BD) on a FACSarray flow cytometer. Thefollowing cytokines were measured: IL-8, IL-1β, IL-10, TNF, IL-12 p70,IL-6. In some experiments, cytokines were measured by ELISA kits fromR&D systems (IL-10, TNF-α, IL-1β) according to the manufacturer'instruction.

Data Analysis

All experiments were performed at least twice, with representativeresults shown. The data presented are expressed as mean plus/minusstandard deviation (SD). Statistical significance was determined by2-way ANOVA with the variables being treatment (hBD2, dexamethazone,etc.) and stimulation (LPS, LTA, peptidoglycan, ect.) followed byBonferroni post-test as reported in the table legends. Differences wereconsidered significant for p<0.05.

Results

The effect of hBD2 was tested on human PBMC treated with and without LPSand LTA (Tables 3, 4 and 5). Treatment with hBD2 gave a significantdownregulation of TNF in stimulated cultures for all three testedconcentrations (Table 3), the downregulation is dose-dependent for LPSat 0.6 ng/ml and for LTA. For IL-1β the downregualtion was observedmostly at the highest doses (Table 4). Interestingly, IL-10 wassignificantly and dose-dependently upregulated (Table 5). Downregulationof proinflammatory cytokines and induction of anti-inflammatorycytokines shows a very strong anti-inflammatory potential of hBD2.Viability was measured by two different assays, in order to exclude thatthe anti-inflammatory effects of hBD2 is due to cytotoxic effects. InTables 6 and 7 it can be seen that hBD2 have no cytotoxic effect on thecells, the observed effects are stimulatory effects due to stimulationwith LPS or LTA that leads to proliferation of the cells. Therefore hBD2has no cytotoxic effect on these cells.

In Tables 8, 9 and 10, supernatants from another donor were analysed forcytokines by ELISA instead of by a cytometric bead array byflowcytometry and here the same were observed, although the sensitivityof the assay is lower and the detection limit much higher and thereforethe effects were not as significant.

In order to test yet another Toll-like receptor ligand, the effect ofhBD2 on peptidoglycan stimulated PBMC was investigated (Tables 11 and12). The same was observed: TNF is dose-dependently downregulated andIL-10 is dose-dependently induced.

As a positive control on downregulation of TNF, two anti-inflammatorycompounds, dexamethasone and Indomethacin, were tested in the assay. Theconcentrations are selected so the compounds are not toxic andachievable concentration due to solubility in medium. Indomethacin onlyinhibited TNF (Table 13) after stimulation with LTA, whereasdexamethasone effectively downregulated TNF production, the same wasobserved for IL-1β (Table 15). Indomethacin is a COX-1 and COX-2inhibitor and is a nonsteroidal anti-inflammatory drug (NSAID) used totreat mild to moderate pain and help relieve symptoms of arthritis anddexamethasone is a synthetic glucocorticoid used primarily in thetreatment of inflammatory disorders and it has very potentdownregualting effect on proinflammatory cytokines (Rowland et al. 1998)at very low doses, which we also observe for TNF-α and IL-1β. hBD2 is aseffective as or better than these two anti-inflammatory compounds.

In Tables 16 and 17, the effect of hBD2 on downregulating TNF in amonocyt cell line and on dendritic cells are shown, the same is observedas was for PBMC. IL-10 was also induced for dendritic cells stimulatedwith hBD2 and LPS or hBD2 and LTA (results not shown).

In order to exclude that binding of hBD2 to LPS or LTA causes thedownregulation of TNF and IL-1β, the effect of hBD2 on stimulation ofPBMC with a synthetic ligand (Pam3CSK4 (TLR2-TLR1 ligand), InvivoGentlrt-pms) was tested. hBD2 was able to downregulate TNF afterstimulation with this ligand as well, indicating that neutralization ofLPS or LTA is not responsible for the observed effect (results notshown). Moreover, stimulation of dendritic cells with a cytokinecocktail containing TNF-α and IL-α together with hBD2 haddown-regulating effect on IL-1β and IL-8 and IL-6 compared tostimulation with a cytokine cocktail alone. Obviously no effect on TNFcould be analyzed, due to stimulation with TNF-α (results not shown).

TABLE 3 TNF production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS or LTA with and without hBD2, allsamples tested on the same donor, representative experiment out of 5donors. TNF, pg/ml hBD2 hBD2 hBD2 (SD) Control 100 μg/ml 10 μg/ml 1μg/ml Medium 7.3 2.9 2.6 4.2 (5.9) (5.1) (6.6) (10.7) LPS 1708.6 634.21076.4 944.8 0.6 ng/ml (428.3) (226.1)*** (278.0)*** (326.6)*** LPS2572.1 1733.9 1306.6 1526.9 20 ng/ml (581.1) (461.3)*** (375.0)***(444.2)*** LTA 1097.4 375.2 494.7 711.5 1.25 μg/ml (293.8) (114.2)***(158.1)*** (282.5)*** TNF measured by Cytometric Bead Array (CBA) on aFACSarray, ***p < 0.001 compared to respective control (bold), analyzedby 2-way ANOVA (N = app. 200 for each data set).

TABLE 4 IL-1β production from human perifieral blood mononuclear cells(PBMC) after treatment with LPS or LTA with and without hBD2, allsamples tested on the same donor, representative experiment out of 5donors. IL-1β, pg/ml hBD2 hBD2 hBD2 (SD) Control 100 μg/ml 10 μg/ml 1μg/ml Medium 4.2 5.3 3.8 4.1 (4.7) (7.1) (5.8) (51.0) LPS 1734.3 81101949.8 1436.2 0.6 ng/ml (347.0) (454.4)*** (396.4)*** (429.7)*** LPS2629.5 1502.1 2273.9 1889.3 20 ng/ml (533.7) (407.5)*** (486.5)***(504.8)*** LTA 748.5 538.3 935.3 986.7 1.25 μg/ml (172.4) (137.3)***(238.0)*** (738.7)*** IL-1β measured by Cytometric bead array (CBA) on aFACSarray, ***p < 0.001 analyzed by 2-way ANOVA (N = app. 200 for eachdata set).

TABLE 5 IL-10 production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS or LTA with and without hBD2, allsamples tested on the same donor, representative experiment out of 5donors. IL-10, pg/ml hBD2 hBD2 hBD2 (SD) Control 100 μg/ml 10 μg/ml 1μg/ml Medium 2.09 2.9 1.6 2.09 (8.65) (4.6) (4.1) (4.3) LPS 63.15 232.7325.7 97.2 0.6 ng/ml (302.5) (61.5)*** (88.2)*** (31.1)* LPS 70.4 383.3355.8 111.3 20 ng/ml (22.8) (133.6)*** (99.5)*** (38.8)** LTA 14.0 175.6136.6 39.9 1.25 μg/ml (226.1) (57.0)*** (44.7)*** (16.9) IL-10 measuredby Cytometric bead array (CBA) on a FACSarray, ***p < 0.001, **p < 0.01,*p < 0.5 analyzed by 2-way ANOVA (N = app. 200 for each data set).

TABLE 6 PBMC viability after 24 h of stimulation measured by a MTSassay. Values having a different subscript letter in rows aresignificantly different tested by 2-way ANOVA followed by Bonferronipost-test. Viability, MTS (Abs 490 nm hBD2 hBD2 hBD2 (SD)) Control 100μg/ml 10 μg/ml 1 μg/ml Medium 1.4 1.2 1.5 1.3 (0.2) (0.05)^(a) (0.2)^(a)(0.2) LPS 1.6 1.6 2.0 1.5 0.6 ng/ml (0.02) (0.1)^(ab) (0.2)^(b) (0.2)LPS 1.5 1.9 1.8 1.6 20 ng/ml (0.1) (0.2)^(b) (0.3)^(ab) (0.3)

TABLE 7 PBMC viability measured by Alamar Blue, one representativeexperiment out of 5 from 5 different donors. Values having a differentsuperscript letter in rows and values having a different superscriptnumber in columns are significantly different tested by 2-way ANOVAfollowed by Bonferroni post-test. Viability, Alamar hBD2 hBD2 hBD2 Blue(RFU (SD)) Control 100 μg/ml 10 μg/ml 1 μg/ml Medium 4097130 39500533683369 4064143  (166631)   (34466)^(a)   (355296)^(a)  (104634) LPS4279424 4831188 4664362 4230588 0.6 ng/ml  (336188)   (67646)^(b)  (147776)^(b)  (139745) LPS 4604671 4765256 4623818 4561739 20 ng/ml (125840)   (41383)^(b)   (56643)^(b)  (138852) LTA 4018914 46641854677870 4148294 1.25 μg/ml   (632833)¹    (154023)^(b, 2)   (10199)^(b, 2)   (182730)¹²

TABLE 8 TNF-alfa secretion from PBMC after stimulation with hBD2, LTA,LPS or combinations hereof. TNF-α, ng/ml hBD2 hBD2 hBD2 (SD) Control 100μg/ml 10 μg/ml 1 μg/ml Medium nd nd nd nd LPS 0.99 0.41 0.59 0.70 0.6ng/ml (0.27)  (0.03)**  (0.08)* (0.18) LPS 1.44 0.53 0.49 1.18 20 ng/ml(0.31)  (0.01)**  (0.05)** (0.42) LTA 0.90 0.21 0.27 0.65 1.25 μg/ml(0.32)  (0.05)*  (0.04)* (0.29) TNF-alfa measured by ELISA, nd: notdetectable, detection limit in assay 0.01 ng/ml, *p < 0.05 compared torespective control, **p < 0.01 compared to respective control

TABLE 9 IL-10 secretion from PBMC after stimulation with hBD2, LTA, LPSor combinations hereof, TNF-alfa measured by ELISA, nd: not detectable,detection limit in assay 0.03 ng/ml IL-10, ng/ml hBD2 hBD2 hBD2 (SD)Control 100 μg/ml 10 μg/ml 1 μg/ml Medium nd nd nd nd LPS nd 0.14 0.04nd 0.6 ng/ml (0.04) (0.0)  LPS nd 0.46 0.34 nd 20 ng/ml (0.04) (0.04)LTA nd nd nd nd 1.25 μg/ml

TABLE 10 IL-1β secretion from PBMC after stimulation with hBD2, LTA, LPSor combinations hereof, IL-1β, ng/ml hBD2 hBD2 hBD2 (SD) Control 100μg/ml 10 μg/ml 1 μg/ml Medium nd nd nd nd LPS 0.318 0.275 0.268 0.2370.6 ng/ml (0.087) (0.015) (0.039) (0.007) LPS 0.920 0.395 0.354 0.638 20ng/ml (0.267)  (0.033)**  (0.013)** (0.159) LTA 0.291 0.281 0.193 0.2241.25 μg/ml (0.092) (0.059) (0.019) (0.030) TNF-alfa measured by ELISA,nd: not detectable, detection limit in assay 0.016 ng/ml, **p < 0.01compared to respective control

TABLE 11 TNF production from human peripheral blood mononuclear cells(PBMC) after treatment with PGN, with and without hBD2; all samplestested on the same donor. TNF, pg/ml hBD2 hBD2 hBD2 (SD) Control 100μg/ml 10 μg/ml 1 μg/ml Medium 0.0 3.6 3.7 3.4 (4.0) (5.3) (6.2) (5.2)PGN 1099.1 274.9 362.0 809.9 40 μg/ml (251.6) (71.6)*** (97.7)***(246.7)*** TNF measured by Cytometric Bead Array (CBA) on a FACSarray,***p < 0.001 compared to respective control, analyzed by 2-way ANOVA (N= app. 200 for each data set).

TABLE 12 IL-10 production from human peripheral blood mononuclear cells(PBMC) after treatment with PGN, with and without hBD2; all samplestested on the same donor. IL-10, pg/ml hBD2 hBD2 hBD2 (SD) Control 100μg/ml 10 μg/ml 1 μg/ml Medium 0.0 3.0 3.6 3.0 (4.1) (9.6) (13.1) (4.8)PGN 381.3 1054.2 523.4 337.8 40 μg/ml (92.3) (179.3)*** (111.5)***(89.1) TNF measured by Cytometric Bead Array (CBA) on a FACSarray, ***p< 0.001 compared to respective control, analyzed by 2-way ANOVA (N =app. 200 for each data set).

TABLE 13 TNF production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS or LTA, with and without hBD2 or twodifferent controls for inhibition of TNF (Dexamethasone andIndomethacin); all samples tested on the same donor. TNF measured byCytometric Bead Array (CBA) on a FACSarray, values underlined aresignificantly reduced compared to respective control (bold), analyzed by2-way ANOVA (N = app. 200 for each data set). TNF, ng/ml LPS LPS LTA(SD) Medium 0.6 ng/ml 20 ng/ml 1.25 μg/ml Control 0.0 1.43 2.84 6.72(0.0) (0.05) (0.07) (0.14) Dexamethason 0.0  0.038 1.69 1.75 35 ng/ml(0.0)  (0.004) (0.05) (0.05) Dexamethason 0.0 0.30 0.91 2.05 3.5 ng/ml(0.0) (0.01) (0.03) (0.06) Dexamethason 0.0 0.61 6.04 4.73 0.35 ng/ml(0.0) (0.02) (0.14) (0.10) Indomethacin 0.0 1.71 2.70 5.80 7.2 ug/ml(0.0) (0.07) (0.07) (0.13) Indomethacin 0.0 1.56 7.54 5.50 0.72 ug/ml(0.0) (0.04) (0.17) (0.13) hBD2 0.0  0.003  0.000 0.11 1000 μg/ml (0.0) (0.002)  (0.002) (0.01) hBD2 0.0  0.000  0.038 1.15 100 μg/ml (0.0) (0.002)  (0.003) (0.04) hBD2 0.0 0.20 0.35 2.33 10 μg/ml (0.0) (0.01)(0.01) (0.06) hBD2 0.0 0.17 6.24 3.90 1 μg/ml (0.0) (0.01) (0.14) (0.10)

TABLE 14 IL-10 production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS or LTA, with and without hBD2 or twodifferent controls for antiinflammatory effects (Dexamethasone andIndomethacin); all samples tested on the same donor. IL-10 measured byCytometric Bead Array (CBA) on a FACSarray, values underlined aresignificantly increased compared to respective control (bold), analyzedby 2-way ANOVA (N = app. 200 for each data set). IL-10, pg/ml LPS LPSLTA (SD) Medium 0.6 ng/ml 20 ng/ml 1.25 μg/ml Control 0.0 53.9  123.4 170.1  (218.8) (3.1) (4.6) (5.5) Dexamethason 0.0 100.4  152.5  175.2 35 ng/ml (1.4) (3.8) (5.2) (6.6) Dexamethason 2.7 64.6  122.8  112.5 3.5 ng/ml (1.9) (3.3) (4.7) (3.9) Dexamethason 3.9 46.8  197.1  126.6 0.35 ng/ml (1.9) (2.8) (7.2) (4.7) Indomethacin 0.0 45.7  77.9  90.4 7.2 ug/ml (1.5) (2.5) (3.6) (4.9) Indomethacin 0.0 37.3  108.0  84.9 0.72 ug/ml (1.4) (19.6)  (4.4) (3.5) hBD2 0.0 30.8  50.5  465.2  1000μg/ml (1.6) (2.6) (3.2) (16.3)  hBD2 0.0 173.5  885.2  766.0  100 μg/ml(4.9) (5.7) (22.2)  (21.7)  hBD2 3.9 165.1  497.5  355.8  10 μg/ml (1.7)(5.6) (13.5)  (9.4) hBD2 0.0 42.7  207.0  142.1  1 μg/ml (1.9) (2.8)(6.9) (4.9)

TABLE 15 IL-1β production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS or LTA, with and without hBD2 or twodifferent controls for antiinflammatory effects (Dexamethasone andIndomethacin); all samples tested on the same donor. IL-1β measured byCytometric Bead Array (CBA) on a FACSarray, values underlined aresignificantly reduced compared to respective control (bold), analyzed by2-way ANOVA (N = app. 200 for each data set). IL-1β, ng/ml LPS LPS LTA(SD) Medium 0.6 ng/ml 20 ng/ml 1.25 μg/ml Control 0.00 3.96 6.58 11.47 (0.06) (0.18) (0.23) (0.38) Dexamethason 0.00 1.00 2.32 3.98 35 ng/ml(0.00) (0.03) (0.07) (0.14) Dexamethason 0.00 1.90 3.58 5.22 3.5 ng/ml(0.00) (0.06) (0.12) (0.19) Dexamethason 0.01 2.9  5.56 7.91 0.35 ng/ml(0.00) (0.09) (0.18) (0.28) Indomethacin 0.04 4.1  6.12 8.91 7.2 ug/ml(0.00) (0.13) (0.23) (0.30) Indomethacin 0.01 3.1  6.46 7.53 0.72 ug/ml(0.00) (0.18) (0.22) (0.31) hBD2 0.01 0.53 1.19 4.43 1000 μg/ml (0.00)(0.02) (0.08) (0.14) hBD2 0.00 0.38 1.67 9.12 100 μg/ml (0.00) (0.01)(0.05) (0.32) hBD2 0.06 1.13 3.58 11.0  10 μg/ml (0.00) (0.04) (0.12)(0.37) hBD2 0.01 1.83 4.91 8.87 1 μg/ml (0.00) (0.06) (0.19) (0.29)

TABLE 16 TNF production in supernatant from a human monocyte cell line(MUTZ-3) after treatment with LPS or LTA, with and without hBD2. TNF,pg/ml hBD2 hBD2 hBD2 (SD) Control 100 μg/ml 10 μg/ml 1 μg/ml Medium 0.000.00 2.60 2.21 (5.56) (5.47) (7.17) (7.88) LPS 6.38 3.93 3.93 6.61 1.5μg/ml (9.28) (6.63)* (6.93)* (9.17) LTA 5.28 2.64 3.76 1.75 1.5 μg/ml(9.75) (29.19)* (7.72) (6.96)** TNF measured by Cytometric Bead Array(CBA) on a FACSarray, *p < 0.05 compared to respective control, **p <0.01 compared to respective control, analyzed by 2-way ANOVA (N = app.200 for each data set).

TABLE 17 TNF production in supernatants from immature dendritic cellsstimulated with LPS or LTA (to generate mature DC), with and withouthBD2. TNF, pg/ml hBD2 hBD2 hBD2 (SD) Control 100 μg/ml 10 μg/ml 1 μg/mlMedium 0.00 0.00 1.89 4.64 (1.74) (1.83) (2.15) (10.26) LPS 23.73 7.6613.8 18.04 1.5 μg/ml (3.28) (2.51)*** (2.33)*** (2.89)*** LTA 3.78 5.222.76 0.00 1.5 μg/ml (2.26) (2.25) (2.27)* (1.98)*** TNF measured byCytometric Bead Array (CBA) on a FACSarray, *significantly reduced p <0.05 compared to respective control, ***significantly reduced p < 0.01compared to respective control, analyzed by 2-way ANOVA (N = app. 200for each data set).

Example 3

Anti-Inflammatory Activity of hBD1, hBD2, hBD3, and a hBD4 Variant

Example 3 was carried out essentially as described in Example 2. Thecompound rhBD2, as shown in the tables below, is recombinant hBD2, whichis identical to hBD2 as used in Example 2.

The compounds hBD1, hBD2, hBD3 and hBD4 variant, as shown in the tablesbelow, were prepared using chemical synthesis, and obtained from PeptideInstitute Inc.

The amino acid sequence of recombinant hBD2 (rhBD2) is identical to theamino acid sequence of hBD2 prepared by chemical synthesis.

The hBD4 variant shown in the tables below consists of amino acids 3-39of hBD4, and the amino acid sequence is shown as SEQ ID NO:5.

In each table, all samples were tested on the same donor. SD meansstandard deviation.

Results

TABLE 18 TNF production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS with and without human beta defensins,dexamethasone or Infliximab. Medium LPS 20 ng/ml LPS 0.6 ng/ml TNF pg/ml% of TNF pg/ml % of TNF pg/ml % of Test compound (SD) control (SD)control (SD) control Medium 1 100% 2164  100%  728 100%  (non-treated)(1) (632) (156) rhBD2 0 — 167  8%  74 10% 40 μg/ml (0)   (17)***   (5)*** rhBD2 0 — 260 12% 125 17% 10 μg/ml (0)   (29)***   (20)**rhBD2 1 — 918 42% 196 27% 1 μg/ml (0)   (373)***  (104)** hBD1 0 — 99946%  91 13% 40 μg/ml (0)   (116)***   (8)** hBD1 0 — 1311  61% 203 28%10 μg/ml (1)   (417)***   (20)** hBD1 1 — 1395  64% 474 65% 1 μg/ml (1)  (201)*** (187) hBD2 0 —  52  2% 176 24% 40 μg/ml (0)   (71)*** (103)** hBD2 0 — 132  6% 304 42% 10 μg/ml (0)   (179)***  (108)* hBD2 0— 411 19% 242 33% 1 μg/ml (0)   (581)***  (30)* HBD-3 0 — 451 21% 52873% 1 μg/ml (0)   (24)***  (98) hBD4 variant 0 — 139  6% 211 29% 10μg/ml (0)    (6)***   (22)** hBD4 variant 0 — 778 36% 468 64% 1 μg/ml(0)   (27)***  (59) Dexamethasone 0 — 635 29%  47  6% (0)   (163)***   (8)*** Infliximab 0 —  0  0%  0  0% (0)    (0)***    (0)*** TNFmeasured by Cytometric Bead Array (CBA) on a FACSarray, *p < 0.05, **p <0.01, ***p < 0.001 analyzed by 2-way ANOVA and compared to non-treatedcells by Bonferroni posttests.

TABLE 19 IL-10 production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS with and without human beta defensins,dexamethasone or Infliximab. Medium LPS 20 ng/ml LPS 0.6 ng/ml IL-10pg/ml % of IL-10 pg/ml % of IL-10 pg/ml % of Test compound (SD) control(SD) control (SD) control Medium 0 100% 111 100% 66 100% (non-treated)(0)  (3)  (5) rhBD2 0 — 281 252% 108  162% 40 μg/ml (0)    (9)***  (4)*rhBD2 0 — 243 218% 103  155% 10 μg/ml (0)   (38)***  (14)* rhBD2 0 — 126113% 72 108% 1 μg/ml (0)  (14)  (9) hBD1 0 — 113 102% 69 104% 40 μg/ml(0)  (5)  (4) hBD1 0 — 100  90% 76 114% 10 μg/ml (0)  (1) (13) hBD1 0 — 95  85% 71 108% 1 μg/ml (0)  (17)  (6) hBD2 0 — 323 290% 131  197% 40μg/ml (0)    (0)***   (13)*** hBD2 0 — 240 215% 86 130% 10 μg/ml (0)   (0)***  (6) hBD2 0 — 123 110% 53  80% 1 μg/ml (0)  (0)  (5) hBD3 0 —152 137% 71 107% 1 μg/ml (0)  (72)*  (2) hBD4 variant 0 — 187 168% 92139% 10 μg/ml (0)    (9)*** (17) hBD4 variant 0 — 175 157% 90 136% 1μg/ml (0)    (8)*** (14) Dexamethasone 0 —  75  67% 47  70% (0)   (6)* (3) Infliximab 0 —  63  56% 46  69% (0)   (7)**  (9) IL-10 measured byCytometric Bead Array (CBA) on a FACSarray, *p < 0.05, **p < 0.01, ***p< 0.001 analyzed by 2-way ANOVA and compared to non-treated cells byBonferroni posttests.

TABLE 20 IL-1β production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS with and without human beta defensins,dexamethasone or Infliximab. Medium LPS 20 ng/ml LPS 0.6 ng/ml IL-1βpg/ml % of IL-1β pg/ml % of IL-1β pg/ml % of Test compound (SD) control(SD) control (SD) control Medium 0 100% 2544 100%  741 100% (non-treated) (0)  (226)  (93) rhBD2 0 —  395 16% 124 17% 40 μg/ml (0)   (25)***   (11)*** rhBD2 0 —  624 25% 214 29% 10 μg/ml (0)    (37)***   (7)*** rhBD2 0 — 1480 58% 284 38% 1 μg/ml (0)   (154)***   (15)***hBD1 0 — 1599 63% 302 41% 40 μg/ml (0)    (14)***    (3)*** hBD1 0 —1913 75% 401 54% 10 μg/ml (0)    (53)***   (17)*** hBD1 0 — 2087 82% 51269% 1 μg/ml (0)   (157)***   (45)** hBD2 1 —  316 12% 159 21% 40 μg/ml(1)    (0)***    (2)*** hBD2 0 —  589 23% 238 32% 10 μg/ml (0)    (0)***  (124)*** hBD2 0 — 1569 62% 312 42% 1 μg/ml (0)    (0)***   (28)***hBD3 0 —  568 22% 331 45% 1 μg/ml (0)   (126)***   (23)*** hBD4 variant0 —  463 18% 163 22% 10 μg/ml (0)    (40)***    (5)*** hBD4 variant 0 —1004 40% 286 39% 1 μg/ml (0)    (24)***   (11)*** Dexamethasone 0 — 112044% 104 14% (0)   (220)***    (8)*** Infliximab 0 — 2704 106%  636 86%(0)   (0)  (81) IL-1β measured by Cytometric Bead Array (CBA) on aFACSarray, ***p < 0.001 analyzed by 2-way ANOVA and compared tonon-treated cells by Bonferroni posttests.

The effects of hBD1, hBD2, hBD3 and a hBD4 variant were tested on humanPBMC treated with and without LPS (Tables 18, 19 and 20). Forcomparison, rhBD2 was included in each setup.

TNF was downregulated for all defensins. The reduction in IL-1βsecretion was comparable to TNF, although not as pronounced as TNF.Secretion of IL-10 was significantly and dose-dependently enhanced forhBD2 and the hBD4 variant.

hBD3 was also tested at 10 μg/ml and 40 μg/ml and the hBD4 variant wasalso tested at 40 μg/ml; however, since both molecules were toxic to thecells at the these concentrations, it was not possible to discriminatebetween toxic and anti-inflammatory effects.

As a positive control on downregulation of TNF, two anti-inflammatorycompounds, Dexamethasone and Infliximab, were included in the setup.

CONCLUSION

All the tested human beta defensins showed anti-inflammatory potential.

Example 4

Reduction of IL-23 from Human Monocyte-Derived Dendritic Cells and HumanPBMCs

Example 4 was carried out essentially as described in Example 2 forhuman PBMCs; however, the readout was IL-23 instead of TNF, IL-1β andIL-10. Moreover, the effect of rhBD2 on human monocyte-derived dendriticcells was also investigated.

Generation of Monocyte-Derived Dendritic Cells (DCs)

The DCs were prepared according to a modified protocol originallydescribed by Romani et al. Briefly, peripheral blood mononuclear cells(PBMCs) were purified from buffy coats of healthy donors bycentrifugation over a Ficoll-pague (GE-healthcare) gradient. Monocyteswere isolated from PBMC by positive selection of CD14+ cells by magneticbeads (Dynal, Invitrogen) according to the manufacturer's instructions.The CD14+ monocytes were cultured in 6-well plates in RPMI/2% Human ABSerum recombinant human recombinant granulocyte-macrophagecolony-stimulating factor (GM-CSF, 20 ng/ml) and IL-4 (20ng/ml)(PeproTech) for 6 days, replenishing the medium/cytokines after 2and 5 days. After 6 days of culture the immature DCs are re-culturedinto 96-well plates in a concentration of 1×10⁶ cells/ml and leftuntreated or treated with a cocktail and/or hBD2 for a further 24 h.hBD2 was tested in four concentrations in quadruplicate. hBD2 wasanalyzed for its ability to suppress hDC-maturation into aproinflammatory phenotype using a proinflammatory cocktail thatcontained LPS (100 ng/ml) and IFN-γ (20 ng/ml). Dexamethasone was added20 h prior to the cocktail as positive control for a compound withproven clinical anti-inflammatory activity. The incubation with hBD2 wasdone 4 h prior to addition of cocktail.

Cytokine ELISA

Cell culture supernatants were collected and stored at −80° C. Amountsof IL-23 was measured by standard sandwich ELISA using commerciallyavailable antibodies and standards according to the manufacturer'sprotocols (eBioscience).

MTT Assay

A MTT based cell growth determination kit was used as a measure of cellsurvival after 48 h in order to evaluate if any of the cells wereseverely affected by treatment with vehicles, cocktail or hBD2 and wasdone according to the manufacturer's protocols (Sigma).

Statistical Analyses

All experiments were performed at least twice, with representativeresults shown. The data presented are expressed as mean plus/minusstandard deviation (SEM). Statistical significance was determined by2-way ANOVA with the variables being treatment (hBD2, dexamethazone,ect.) and stimulation (LPS, LTA, peptidoglycan, ect.) followed byBonferroni post-test as reported in the table legends. Differences wereconsidered significant for p<0.05.

Results

TABLE 21 IL-23 (pg/ml) in supernatants of human CD14⁺ monocyte-deriveddendritic cells stimulated with either medium (unstimulated), or LPS andIFN-γ and treated with either medium (untreated), hBD2 or Dexamehtasone,average (SEM), N = 4, one representative donor out of three. IL-23 pg/mlLPS (100 ng/ml) and (SEM) Unstimulated IFN-γ (20 ng/ml) Untreated 3753569  (96)  (130) hBD2 nd 3833 1 μg/ml  (88) hBD2 451 3308 10 μg/ml(121)  (169)* hBD2 nd 3042 30 μg/ml    (46)*** hBD2 nd 2145 100 μg/ml  (202)*** Dexamethasone 424 1147 1 μM  (38)   (268)*** *p < 0.05, **p <0.01, ***p < 0.001 analyzed by 2-way ANOVA and compared to non-treatedcells by Bonferroni posttests. nd: not detected (below detection limit).

TABLE 22 IL-23 (pg/ml) in supernatants of human PBMC stimulated witheither medium (control), 0.6 ng/ml LPS, 20 ng/ml LPS or 5 μg/ml LTA andtreated hBD2, Dexamehtasone or Infliximab, average (SEM). IL-23 pg/mlLPS LPS LTA (SEM) Control 0.6 ng/ml 20 ng/ml 5 μg/ml Control 257 553 510762 (non-treated)  (7)  (6)  (5)  (20) hBD2 218 338 263 383 1 μg/ml  (5)  (10)**   (5)**   (20)** hBD2 211 462 295 438 10 μg/ml  (4)   (2)*  (1)**   (9)** hBD2 207 484 488 810 100 μg/ml  (4)  (7)  (8)  (30)Dexamethasone 222 202 192 223 3.5 ng/ml  (5)   (5)**   (1)**   (1)**Infliximab 227 356 373 349 1 μg/ml  (10)   (10)**   (2)**   (1)** *p <0.05, **p < 0.01, ***p < 0.001 analyzed by 1-way ANOVA and compared tonon-treated cells by Dunnett's Multiple Comparison posttest.

As shown in Table 21, hBD2 suppresses significantly and dose-dependentlyIL-23 secretion from human CD14⁺ monocyte-derived dendritic cells.

For human PBMC, IL-23 secretion was also significantly suppressed (Table22). On these cells there was an inverse dose-dependency, that was foundto be a bell-shaped dose-response inhibition curve when testing lowerdoses of hBD2 (data not shown).

This shows that hBD2 might have a suppressive effect in a chronicautoimmune condition by suppression of IL-23 secretion, as IL-23 is animportant part of the inflammatory response. Th17 cells are dependent onIL-23 for their survival and expansion, and Th17 cells have been shownto be pathogenic in several autoimmune diseases, such as Crohn'sdisease, ulcerative colitis, psoriasis and multiple sclerosis.

Example 5

Reduction of TNF Secretion from PBMCs with Mouse Beta Defensin 3 (mBD3)

Example 5 was carried out essentially as described in Example 2 forhuman PBMCs. Mouse beta defensin 3 (mBD3) was prepared using the sameprotocol as was used for production of hBD2 in Example 1. The amino acidsequence of mBD3 is shown in SEQ ID NO:6. Mouse PBMCs were prepared asdescribed below.

Isolation and Stimulation of Mouse Peripheral Blood Mononuclear Cells(PBMC)

Mouse peripheral blood mononuclear cells were isolated from blood of tenNMRI mice. In short, heparinized blood was diluted 1/1 v/v with RPMI andsubjected to Ficoll density centrifugation within 2 h of drawing. Plasmawas collected from the top and discarded. Isolated PBMC were resuspendedin culture medium (RPMI 1640 (Gibco, 42401) w/1% penicillin andstreptomycin and 1% L-Glutamine) and seeded in 96-well culture plateswith 115.500 cells per well in a total of 200 μl. PBMC from the samedonor were stimulated with 100, 10 or 1 μg/ml of hBD2 or mBD3 (mousebeta defensin 3); either alone or together with 20 ng/ml LPS (E. coli,O111:B4, Sigma L4391). Dexamethasone was added at 3.5 ng/ml to cultureswith and without LPS stimulation. The supernatants were collected afterincubation at 37° C. for 24 hours, and stored at −80° C. until cytokinemeasurement.

Cytokine production in supernatants was measured by flow cytometry witha mouse inflammation cytometric bead array (CBA) according tomanufacturer's instructions (BD) on a FACSarray flow cytometer.

Viability was measured by Alamar Blue (Biosource DALL 1100) aftersupernatant were collected.

Results

TABLE 23 TNF production from human peripheral blood mononuclear cells(PBMC) after treatment with LPS with and without hBD2, all samplestested on the same donor, representative experiment out of two donors.TNF pg/ml LPS (SEM) Medium 20 ng/ml Medium 5 1353  (1) (140) mBD3 2 3841 μg/ml (0)   (11)*** mBD3 2  51 10 μg/ml (0)    (1)*** mBD3 39  166 100μg/ml (19)    (17)*** hBD2 3 633 1 μg/ml (0)   (110)*** hBD2 2 359 10μg/ml (0)   (10)*** hBD2 2 342 100 μg/ml (0)   (34)*** Dexamethasone 1460 3.5 ng/ml (0)   (29)*** Infliximab 0  1 1 μg/ml (0)    (0)*** TNFmeasured by Cytometric Bead Array (CBA) on a FACSarray, ***p < 0.001compared to respective control, analyzed by 2-way ANOVA (N = 2).

TABLE 24 TNF production from mouse peripheral blood mononuclear cells(PBMC) after treatment with LPS with and without mBD3, all samplestested on the same donor, representative experiment out of two donors.TNF pg/ml LPS (SEM) Medium 20 ng/ml Medium 578 2063   (3)  (77) mBD3 3471600  1 μg/ml  (32)   (47)*** mBD3 180 297 10 μg/ml  (0)    (9)*** mBD3182 195 100 μg/ml  (5)    (6)*** Dexamethasone  94 328 3.5 ng/ml  (3)   (8)*** Infliximab 530 2119  1 μg/ml  (4)  (31) TNF measured byCytometric Bead Array (CBA) on a FACSarray, ***p < 0.001 compared torespective control, analyzed by 2-way ANOVA (N = 2).

As shown in Table 23, mouse beta defensin 3 (mBD3) is downregulating thesecretion of TNF from human PBMCs to the same extend as hBD2 anddexamethason. mBD3 also downregulate the secretion of TNF from mousePBMC (Table 24).

Accordingly, in this setup, mBD3 exhibits excellent anti-inflammatoryactivity.

REFERENCES

-   Bonoiotto M., W J Jordan, J. Eskdale, A. Tossi, N. Antcheva, S.    Crovella, N D Connell and G Gallagher. Human β-Defensin 2 Induces a    Vigorous Cytokine Response in Peripheral Blood Mononuclear Cells.    Antimicrobial Agents and Chemotherapy (2006), 50, 1433-1441.-   Bowdish et al., Immunomodulatory properties of defensins and    cathelicidins. Curr. Top. Microbiol. Immunol. (2006) 306, 27-66.-   Gersemann et al., Crohn's disease—defect in innate defence. World J.    Gastroenterol. (2008) 14, 5499-5503.-   Lehrer R. I., Primate defensins. Nat. Rev. Microbiol. (2004) 2,    727-738.-   Swidsinski et al., Mucosal flora in inflammatory bowel disease.    Gastroenterology (2002) 122, 44-54.-   Niyonsaba F., H. Ushio, N. Nakano, W. Ng, K. Sayama, K.    Hashimoto, I. Nagaoka, K. Okumura and H. Ogawa. Antimicrobial    peptides human β-defensins stimulate epidermal keratinocyte    migration, proliferation and production of proinflammatory cytokines    and chemokines. Journal of Investigative Dermatology (2007), 127,    594-604.-   Rowland T L, S M McHugh, J Deighton, R J Dearman, P W Ewan and I    Kimber. Differential regulation by thalidomide and dexamethasone of    cytokine expression in human peripheral blood mononuclear cells.    Immunopharmacology (1998), 40, 11-20.-   Wang et al., Host-microbe interaction: mechanisms of defensin    deficiency in Crohn's disease. Expert. Rev. Anti. Infect.    Ther. (2007) 5, 1049-1057.-   Wehkamp et al., Reduced Paneth cell alpha-defensins in ileal Crohn's    disease. Proc. Natl. Acad. Sci. U. S. A (2005) 102, 18129-18134.

1. A method of treating an rheumatoid arthritis, comprisingadministering to a subject in need of such treatment an effective amountof a beta-defensin comprising an amino acid sequence that has at least85% identity to the amino acid sequence of SEQ ID NO:
 5. 2. The methodof claim 1, wherein the beta-defensin is administered orally.
 3. Themethod of claim 1, wherein the beta-defensin is administeredparenterally.
 4. The method of claim 3, wherein the beta-defensin isadministered subcutaneously or intravenously.
 5. The method of claim 1,wherein the beta-defensin is administered at a daily dosage of fromabout 0.1 mg/kg body weight to about 100 mg/kg body weight.
 6. Themethod of claim 1, wherein the beta-defensin is administered at a dailydosage of from about 0.1 mg/kg body weight to about 10 mg/kg bodyweight.
 7. The method of claim 1, wherein the beta-defensin comprisesthe amino acid sequence of SEQ ID NO:
 5. 8. The method of claim 1,wherein the beta-defensin consists of the amino acid sequence of SEQ IDNO:
 5. 9. The method of claim 1, wherein the beta-defensin comprisesconserved cysteine residues corresponding to amino acid positions 8, 15,20, 30, 37, 38 of SEQ ID NO:
 5. 10. The method of claim 1, wherein anyamino acid substitution in the beta-defensin relative to SEQ ID NO: 5 isa conservative substitution.
 11. A method of treating rheumatoidarthritis, comprising administering parenterally to a subject in need ofsuch treatment an effective amount of a beta-defensin comprising theamino acid sequence of SEQ ID NO: 5.